A Multicenter Retrospective Study of the Safety and Efficacy of Nivolumab (Nivo) in Combination with Doxorubicin, Vinblastine, and Dacarbazine (AVD) for the Frontline Treatment of Advanced Stage Hodgkin Lymphoma (HL) – A Real-World Study Read more
Real world outcomes of patients with limited-stage diffuse large B-cell lymphoma treated with abbreviated R-CHOP immunochemotherapy Read more
Impact of Salvage Therapy on Outcomes in Patients with Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma Prior to Autologous or Allogeneic Stem Cell Transplant Read more
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) Read more
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Read more
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) Read more
An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy. Read more
